Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Biomarker / Assay15 Peer-Reviewed Briefings
HbA1c, Insulin & Glycemic Control
Glycated hemoglobin, fasting insulin sensitivity, HOMA-IR, and continuous glucose time-in-range.
Active Specialties:CardiologyNephrologyEndocrinologyInfectious DiseaseGastroenterology
Full-fat dairy may not be the metabolic villain once thought, prompting a review of dietary advice. These findings suggest current dietary guidelines regarding dairy consumption may need re-evaluation, potentially impacting patient counseling.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
This review positions cellular energetics as an important upstream constraint shaping kidney disease progression, offering a foundation for nephroprotective strategies. This framework integrates spatial cortex-medulla vulnerability, reconciles early hemodynamic changes with durable slowing of estimated glomerular filtration rate decline, and explores disease-agnostic benefit.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Hypoglycemia was associated with a transient period of cognitive vulnerability largely confined to the hour after an event, with little evidence of delayed effects. Findings support avoiding or exercising caution during cognitively demanding tasks for up to an hour after a hypoglycemic event.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Our results indicate that individuals with combined autoimmunity and lower insulin sensitivity present with clinical diabetes earlier than classic type 1 diabetes along the β-cell decline trajectory, identifying a potential timeframe for disease-modifying interventions in specific type 1 diabetes subtypes. Adult-onset type 1 diabetes exhibits substantial heterogeneity.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
This review will serve as a practical guide for cardiologists to manage a potentially reversible contributor to poor CKM control. Therapeutic strategies include adrenal steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed therapies in selected cases, while surgery remains the first-line treatment for surgically remediable disease.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events. To evaluate the efficacy (real-world effectiveness in the trial) and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
A better understanding of the differences between metabolically divergent groups and the physiological responses to weight loss can help identify the factors responsible for the link between excess adiposity and metabolic dysfunction and disease. In this Review, we discuss metabolic differences at the cellular, organ-system and systemic levels between people with metabolically healthy and metabolically unhealthy obesity; we also discuss heterogeneity in the therapeutic effects of weight reduction.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Intermittent miricorilant dosing of 100 mg twice weekly achieved meaningful reductions in LFC and improved liver health markers with a favorable safety profile. Miricorilant, an oral nonsteroidal selective glucocorticoid receptor modulator, is being investigated as a therapy that modulates hepatic cortisol activity in patients with metabolic dysfunction-associated steatohepatitis (MASH).
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In women with PCOS and MASLD, saroglitazar significantly improved hepatic steatosis, liver enzymes, lipid profile, and FibroScan AST score. These findings support further evaluation of saroglitazar in larger studies in women with PCOS.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
CGMS-guided insulin optimization was associated with improvements in glucose control and nutritional status. Published in Diabetes care, these peer-reviewed endocrinology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile, supporting Phase 3 evaluation. UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Care location choice shifts dynamically with age and school transitions, with restroom use being linked to poorer glycemic control. Supporting youth during school transitions requires targeted environmental adjustments and enhanced school-wide understanding to ensure safe and appropriate care locations.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In this single-arm, 13-week trial in adults with insulin-treated type 2 diabetes, AID with the twiist system was safe and associated with substantially improved glycemia. Published in Diabetes care, these peer-reviewed endocrinology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min read·Diabetes Care·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”